Phytanic acid-d3

Phytanic acid-d3 is the deuterium labeled Phytanic acid[1]. Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease[2][3][4][5][6].

Product Specifications

CAS Number

[1383920-40-8]

UNSPSC

12352211

Hazard Statement

H225, H350

Target

Endogenous Metabolite

Type

Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Concentration

31.65 mM * 100 μL in Ethanol

Purity

99.1

Solubility

10 mM in DMSO

Smiles

CC(C)CCCC(C)CCCC(C)CCCC(C([2H])([2H])[2H])CC(O)=O

Molecular Formula

C20H37D3O2

Molecular Weight

315.55

Precautions

H225, H350

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Budden SS, et al. Dysmorphic syndrome with phytanic acid oxidase deficiency, abnormal very long chain fatty acids, and pipecolic acidemia: studies in four children. J Pediatr. 1986 Jan;108 (1) :33-9.|[3]McLean BN, et al. A new defect of peroxisomal function involving pristanic acid: a case report. J Neurol Neurosurg Psychiatry. 2002 Mar72 (3) :396-9.|[4]Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov44 (5) :720-30. |[5]Poll-The BT, et al. Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis. 19869 (2) :169-74.|[6]Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug39 (35) :5709-5720.